Skip to main content

Bruce Kendall Burnett

Adjunct Associate Professor in the Department of Medicine
Medicine, Clinical Pharmacology
Duke Box 90535, Durham, NC 27715
701 W Main Street, Suite 500, Durham, NC 27701

Selected Grants


Consultation for the Stanford Microbiome Therapies Initiative

ResearchPrincipal Investigator · Awarded by Stanford University · 2019 - 2024

Bruce Burnett IPA

ResearchDirector · Awarded by National Institutes of Health · 2019 - 2020

Biodosimetry High-Throughput Test RFP-16-100-SOL-00010

ResearchRegulatory Director · Awarded by DxTerity Diagnostics · 2017 - 2019

Systemically administrered EGRFvIII-targeted bispecific antibody as an immunotherapeutic for glioblastoma.

FellowshipCollaborator · Awarded by National Institutes of Health · 2015 - 2019

Consultation for the Stanford Microbiome Therapies Initiative

ResearchPrincipal Investigator · Awarded by Stanford University · 2019 - 2024

Bruce Burnett IPA

ResearchDirector · Awarded by National Institutes of Health · 2019 - 2020

Biodosimetry High-Throughput Test RFP-16-100-SOL-00010

ResearchRegulatory Director · Awarded by DxTerity Diagnostics · 2017 - 2019

Systemically administrered EGRFvIII-targeted bispecific antibody as an immunotherapeutic for glioblastoma.

FellowshipCollaborator · Awarded by National Institutes of Health · 2015 - 2019

Duke CTSA (UL1)

ResearchCo Investigator · Awarded by National Institutes of Health · 2013 - 2018

Immunology Quality Assesment Program Option 2

ResearchRegulatory Director · Awarded by National Institutes of Health · 2014 - 2017

Regulatory Guidance for Academic Research of Drugs and Devices

ResearchProgram Director · Awarded by University of North Carolina - Chapel Hill · 2017 - 2017

Point of Care Biodosimeter

ResearchRegulatory Director · Awarded by Department of Health and Human Services · 2009 - 2016

Phase I CTU Task Area A: Administrative and Overal Clinical Operations Support and Concept Development

Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2014 - 2015

PTN Task Order #4: Hydroxyurea PK

ResearchCo Investigator · Awarded by National Institutes of Health · 2011 - 2014

Clinical Trial Planning in Pompe Disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2013 - 2014

Novel Ondansetron Formulation for Combination Treatment of Psychostimulant Abuse

Clinical TrialRegulatory Administrator · Awarded by National Institutes of Health · 2009 - 2013

CTSA UL

ResearchRegulatory Director · Awarded by National Institutes of Health · 2006 - 2012

External Relationships


  • AegisCN LLC
  • Immunity Bio (formerly Nantworks, formerly Etubics)
  • LadeRx, LLC
  • NIH
  • Stanford University School of Medicine
  • AegisCN LLC
  • Immunity Bio (formerly Nantworks, formerly Etubics)
  • LadeRx, LLC
  • NIH
  • Stanford University School of Medicine
  • T3D Therapeutics Inc

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.